Ding Q, Zhang Y, Sun X
Huashan Hospital of Shanghai Medical University.
Zhonghua Bing Li Xue Za Zhi. 1997 Aug;26(4):211-3.
To study the expression of cancer gene product and anti-cancer gene product in the same bladder cancer.
Immunohistochemical staining was used to determine the expression of P21, p53 and proliferating cell nuclear antigen (PCNA) in 5 normal bladder tissues and 58 bladder cancers.
No P21, p53 and PCNA were expressed in the 5 normal bladder tissue samples. The positive incidence of P21, p53 and PCAN expression in the bladder cancers were 62.1%, 55.2% and 58.6% respectively. p53 and PCNA were located in cell nuclei and P21 located on the cell membrane in bladder cancer. The expression of P21, p53 and PCNA correlated to the stage, clinical grade and patient survival rates of this tumor.
These results suggest that P21, p53 and PCNA immunolabelling may be used to determine the prognosis of bladder cancer patients.
研究同一膀胱癌中癌基因产物和抗癌基因产物的表达情况。
采用免疫组织化学染色法检测5例正常膀胱组织和58例膀胱癌组织中P21、p53和增殖细胞核抗原（PCNA）的表达。
5例正常膀胱组织样本中未检测到P21、p53和PCNA的表达。膀胱癌组织中P21、p53和PCAN表达的阳性率分别为62.1%、55.2%和58.6%。在膀胱癌中，p53和PCNA定位于细胞核，P21定位于细胞膜。P21、p53和PCNA的表达与该肿瘤的分期、临床分级及患者生存率相关。
这些结果表明，P21、p53和PCNA免疫标记可用于判断膀胱癌患者的预后。
